AVBP Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
5.0M
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
5.0M
0
0
0
0
Operating Expenses
48.4M
-8.2%
52.7M
+14.3%
46.1M
+18.8%
38.8M
+1.3%
38.3M
R&D
38.9M
-8.1%
42.3M
+12.6%
37.6M
+16.9%
32.2M
+0.0%
32.2M
SG&A
9.5M
-8.4%
10.4M
+21.9%
8.5M
+27.8%
6.6M
+8.1%
6.1M
Operating Income
-43376000
+17.7%
-52691000
-14.3%
-46111000
-18.8%
-38823000
-1.3%
-38316000
EBITDA
-44029000
+16.4%
-52691000
-12.9%
-46670000
-11.5%
-41849000
-9.2%
-38316000
Net Income
-40313000
+19.2%
-49893000
-15.2%
-43320000
-21.9%
-35544000
-1.6%
-34978000
EPS (Basic)
$-0.81
+22.9%
$-1.05
-9.4%
$-0.96
-15.7%
$-0.83
+0.0%
$-0.83
EPS (Diluted)
$-0.81
+22.9%
$-1.05
-9.4%
$-0.96
-15.7%
$-0.83
+0.0%
$-0.83
Shares (Diluted)
49.5M
+4.0%
47.6M
+5.6%
45.1M
+4.7%
43.0M
+2.7%
41.9M
ArriVent BioPharma (AVBP) — Financials